MedTrace Logo

Optimal Haloperidol Dose for Postoperative Nausea and Vomiting Prevention in High-risk Patients

NCT01639599 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2020-09-09

Study results available
· View outcomes & findings →

Summary

Low-dose haloperidol is known to be effective for the treatment of postoperative nausea and vomiting (PONV). However, precise dose-response studies have not been completed, especially in patients at high risk for PONV who require combination therapy. This study sought to identify the optimal dose of haloperidol that could be combined with dexamethasone without adverse effects in high-risk PONV patients receiving intravenous patient-controlled anesthesia (IV PCA) after gynecological laparoscopic surgery.

Conditions

  • Gynecological Disease

Interventions

DRUG

Dexamethasone iv injection

Dexamethasone 5mg iv during anesthesia induction

DRUG

Dexamethasone, haloperidol

dexamethasone + haloperidol 1mg

DRUG

Dexamethasone, haloperidol

Active Comparator: dexamethasone + haloperidol 2mg

Sponsors & Collaborators

  • The Catholic University of Korea

    lead OTHER

Principal Investigators

  • Y.E. Moon, MD · associate proffesor

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2012-12-31
Completion
2013-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01639599 on ClinicalTrials.gov